• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Moderna Inc (NQ: MRNA )

    54.63 +0.27 (+0.50%)
    Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Moderna Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    S&P 500 Briefly Hits Record High Just Ahead Of Fed Rate Cut, Extends 7-Day Winning Streak: Tuesday's Top 5 Gainers
    S&P 500 hits new record highs amidst expectations for Fed interest rate decision. Small-cap stocks outperform, while uncertainty remains. 
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Momentum Investing Gives You An Edge, Until It Doesn’t
    Since 2020, momentum investing has generated significantly better returns than other strategies. Such is not surprising, given the massive amounts of stimulus injected into the financial system. 
    Via Talk Markets
    16 Analysts Have This To Say About Moderna
    Via Benzinga
    Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years
    Via Benzinga
    Tradepulse Power Inflow Alert: Moderna Inc. Rises 8.9% On The Trading Day
    Via Benzinga
    Small Caps, Bitcoin Rally As Traders Await Fed Rate Cut; Treasury Yields, US Dollar Tick Up On Strong Retail Sales: What's Driving Markets Tuesday?
    Wall Street experienced a slightly positive session Tuesday, supported by investor optimism as the Federal Open Market Committee (FOMC) kicked off its two-day meeting, expected to deliver the first... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    What's Going On With Moderna Shares Tuesday?
    Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 vaccine. 
    Via Benzinga
    Exposures COVID-19
    Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
    Via ACCESSWIRE
    MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
    Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration urges healthcare providers to prioritize alternative vaccines for seniors and... 
    Via Benzinga
    Exposures COVID-19
    Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
    Moderna Inc. (NASDAQ: MRNA) made headlines during the pandemic for its messenger ribonucleic acid (mRNA) technology used in its COVID-19 vaccine Spikevax. 
    Via MarketBeat
    Exposures COVID-19 Product Safety
    Moderna, Tyson Foods And Adobe Are Among Top 10 Large Cap Stock Losers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
    10 worst performing large-cap stocks last week: RTO, ALLY, MRNA, HUM, TSN, BEKE, ADBE, RYAAY, JPM, DVN. Consider impact on your portfolio. 
    Via Benzinga
    Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
    This highflier has fallen on hard times recently. 
    Via The Motley Fool
    Wall Street's Top 10 Stock Calls This Week - Saturday, Sept. 14
    What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024. 
    Via Talk Markets
    Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
    Financial factors aren't the only things that are worth paying attention to. 
    Via The Motley Fool
    After Moderna's Shocking News, Is the Stock a Buy or a Sell?
    Moderna held its annual R&D day this week. 
    Via The Motley Fool
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
    Moderna announces plans to reduce R&D spending by $1.1 billion by 2027, focusing on ten key products. Analysts highlight near-term challenges, lowered price targets, and a delayed breakeven to 2028,... 
    Via Benzinga
    Oracle To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
    The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday. 
    Via Investor's Business Daily
    Should You Buy Novavax Stock After This Regulatory Win?
    The biotech continues to earn important wins, but is it enough? 
    Via The Motley Fool
    A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
    These players have had their ups and downs -- but the future looks bright. 
    Via The Motley Fool
    Wall Street Eyes Strong Finish To The Week Despite Futures Suggesting Moderation In Tech Buying: Strategist Cautions Against Factoring Rapid, Steep Cuts Ahead Of Next Week's Fed Meeting
    Now that the twin inflation reports are in the rearview mirror, U.S. stocks are hanging onto the slender optimism as traders look ahead to the Federal Reserve’s rate-setting meeting. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
    Moderna announced plans to slash its R&D budget by $1.1 billion by 2027. 
    Via Talk Markets
    Why Are Novavax Shares Trading Lower Today?
    Novavax Inc. (NASDAQ: NVAX) shares are trading lower Thursday following multiple significant announcements. Here's what you need to know. 
    Via Benzinga
    Stocks Edge Up As Producer Inflation Supports Rate Cut Bets, Small Caps, Miners Rally: What's Driving Markets Thursday?
    At midday on Thursday, Wall Street was showing slight gains, with small caps leading the charge. The Russell 2000 index surged 1.2%, outperforming large-cap indices in a notable rebound. 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Moderna Outlines Post-Covid Roadmap, Cuts Research Budget, Forecasts 2025 Sales Below Expectations
    Moderna highlights its mRNA pipeline and financial strategy at R&D Day and aims for 10 product approvals by 2027, expects to reduce R&D spending by $1.1 billion, and projects profitability for its... 
    Via Benzinga
    Nasdaq, S&P 500 Set For Modest Gains As Investors Eye August Inflation Data And ECB Rate Decision
    U.S. stocks could open Thursday’s session modestly higher after the remarkable recovery they staged in the previous session. The spotlight is on the producer price inflation report for August as... 
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
    The company says it's investment in R&D has paid off. Now, it needs to move its focus to launching new products. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.